Product image of Invokana (Canagliflozin) supplied by GNH India

Invokana

Active Ingredient:
Canagliflozin
Origin:
EU

Invokana (Canagliflozin)

Canagliflozin, the active ingredient in Invokana, is a sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower elevated blood glucose levels.

GNH India supplies Invokana as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support.

Manufacturer / TM Owner

Janssen-Cilag International Nv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Invokana belongs to the SGLT2 inhibitor class and is used to improve glycaemic control in diabetes.

  • Type 2 diabetes mellitus (monotherapy): reduces fasting plasma glucose and HbA1c levels when used alone.
  • Type 2 diabetes mellitus (add‑on therapy): provides additional glucose lowering when combined with metformin or other oral agents.
  • Type 2 diabetes mellitus (renal protection): may slow progression of diabetic kidney disease in eligible patients.

How It Works

  • Canagliflozin selectively inhibits the sodium‑glucose co‑transporter‑2 (SGLT2) located in the proximal renal tubules, blocking reabsorption of filtered glucose. This action increases urinary glucose excretion, thereby lowering plasma glucose concentrations and contributing to improved glycaemic control in patients with type 2 diabetes.

Side Effects

Adverse reactions may occur with canagliflozin therapy.

Common Side Effects

  • Genital mycotic infection: itching or discharge in the genital area.
  • Urinary tract infection: dysuria, frequency, or urgency.
  • Increased urination: polyuria and related thirst.
  • Mild hypotension: dizziness or light‑headedness, especially on standing.
  • Nausea: occasional stomach upset.

Serious or Rare Side Effects

  • Ketoacidosis: metabolic acidosis with elevated ketone bodies.
  • Acute kidney injury: sudden decline in renal function.
  • Fournier's gangrene: necrotizing fasciitis of the perineum.
  • Severe dehydration: marked fluid loss leading to hypotension.
  • Anaphylactic reaction: life‑threatening allergic response.

Precautions & Warnings

When prescribing canagliflozin, several safety considerations are recommended.

  • Renal function monitoring: assess eGFR before initiation and periodically thereafter.
  • Ketoacidosis risk: educate patients to recognize symptoms and discontinue if they occur.
  • Cardiovascular status: evaluate for heart failure or hypotension.
  • Concomitant diuretics: adjust dosage to avoid excessive volume depletion.
  • Genital infection hygiene: advise proper personal care to reduce infection risk.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Canagliflozin may interact with other medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid)

  • Insulin: increased risk of hypoglycaemia.
  • Sulfonylureas: heightened hypoglycaemic potential.
  • Loop diuretics: may exacerbate dehydration and hypotension.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: possible additive blood‑pressure lowering effect.

  • NSAIDs: potential impact on renal function.
  • Rifampin: may reduce canagliflozin exposure.
  • Thiazide diuretics: monitor for volume depletion.
  • Warfarin: occasional alteration of INR, require closer monitoring.

Frequently Asked Questions

Invokana contains canagliflozin, an SGLT2 inhibitor approved to improve blood‑sugar control in adults with type 2 diabetes mellitus, either as a single therapy or in combination with other antidiabetic agents.

Canagliflozin blocks the sodium‑glucose co‑transporter‑2 in the kidney’s proximal tubules, reducing reabsorption of filtered glucose. The excess glucose is expelled in the urine, which lowers circulating blood‑glucose levels.

The specific dose of Invokana is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety of canagliflozin in pregnancy or lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified clinician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Invokana (canagliflozin) shares the core SGLT2 inhibition mechanism with other agents in the class, but it has a distinct efficacy and safety profile, including a higher affinity for SGLT2 and documented renal‑protective benefits in certain patient populations.

Store Invokana tablets at room temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight to maintain potency.

Invokana is taken orally, usually once daily in the morning, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water.

Serious risks include diabetic ketoacidosis, severe dehydration, acute kidney injury, and rare but life‑threatening infections such as Fournier’s gangrene. Patients should be educated to recognize early signs and seek immediate medical attention.

Invokana is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), those on dialysis, individuals with a history of recurrent genital mycotic infections, and patients with known hypersensitivity to canagliflozin or any excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Canagliflozin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT